Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Vogelzang on Two Analyses of the ALSYMPCA Trial

July 10th 2013

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Survival Benefit Propels Prostate Cancer Vaccine to Phase III Trial

July 3rd 2013

An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC).

Lack of PSA Screening Leads to Poor Prognosis in Prostate Cancer

June 27th 2013

Prostate cancer prognosis remains poor for patients who have a prostate-specific antigen level ≥100 ng/mL at discovery, a review of cancer registry data showed.

Dr. Gulley on the Adverse Event Profile for PROSTVAC

June 27th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute (NCI), gives an overview of the adverse event profile for PROSTVAC.

Abiraterone Slows mCRPC Before Chemotherapy

June 21st 2013

Progression-free survival doubled in men with metastatic castration-resistant prostate cancer with no chemotherapy exposure who were treated with abiraterone acetate plus prednisone versus prednisone alone.

Dr. Shore on Immunotherapies for Prostate Cancer

June 20th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Dr. George on Radium-223 in Advanced Prostate Cancer

June 18th 2013

Daniel J. George, MD, from the Duke Cancer Institute, elaborates on the incorporation of radium-223 into the treatment of patients with metastatic castration-resistant prostate cancer.

Optimal Radiation Delivery Methods and Dosing Strategies Under Study

June 17th 2013

The quest to deliver optimal radiation therapy for patients with prostate cancer has led to a variety of advances in technologies and techniques, yet key questions remain unanswered.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

CRPC Challenge: Sequencing Chemotherapy With New Agents

June 12th 2013

Challenges remain regarding the mechanisms of docetaxel resistance, whether combination studies continue to make sense, and how the sequencing of docetaxel may impact toxicity and efficacy.

BRCA1/2 Linked to Poor Prognosis in Prostate Cancer

June 7th 2013

A new study suggests that germline mutations of BRCA1/2 could play a significant role in more-aggressive cases of prostate cancer. Additionally, BRCA2 mutations were specifically linked to poor overall survival.

Active Surveillance Key to Limiting PSA-Related Overtreatment, but Remains Difficult Sell

May 31st 2013

Active surveillance for low-grade prostate cancer has long been considered the elusive "holy grail" for mitigating the overtreatment effect of PSA screening.

Dr. Gomella Discusses the PSA Screening Debate in 2013

May 31st 2013

Leonard G. Gomella, MD, chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

Dr. Cooperberg on the Impact of Prostate Cancer Screening

May 29th 2013

Matthew Cooperberg, MD, MPH, from the UCSF Helen Diller Family Comprehensive Cancer Center, describes the future and historical impact of screening in prostate cancer.

Screening Remains Critical to Optimal Management of Prostate Cancer

May 28th 2013

The mortality rate from prostate cancer has declined significantly in the past few decades; however, there is much debate over how much PSA screening contributed to that decline.

Dr. Deepak Kapoor Discusses PSA Screening Guidelines

May 22nd 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, provides his opinion on current prostate cancer screening recommendations.

Dr. Morris on rPFS as an Endpoint in Clinical Trials

May 22nd 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Dr. Sandler on Radiation Therapy for Prostate Cancer

May 21st 2013

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

Dr. Crawford on Sequences and Combinations in CRPC

May 20th 2013

E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.

Beyond Provenge: The Next Steps With Immunotherapy in Prostate Cancer

May 17th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.

NEXT PAGE
PREVIOUS PAGE